Email: susan.bowler2@nhs.net
Telephone: 0113 82 49143
Our Ref: SSC1884 - Cabozantinib

Specialised Commissioning – Midlands & East
Fosse House
6 Smith Way
Grove Park
Enderby
Leicestershire
LE19 1SX

Tel: 0116 206 0185

5 July 2018

Emailed to:
East Midlands Acute Providers
Medical Directors

Dear Medical Director

NICE Technology Appraisal 516: Cabozantinib for treating medullary thyroid cancer

I am writing to advise you regarding NHS England's position on the recently published NICE Technology Appraisal guidance for cabozantinib for treating medullary thyroid cancer. The guidance can be found at: https://www.nice.org.uk/guidance/ta516

NICE, in their Technology Appraisal (TA 516) published 28th March 2018, have stated that:

> Cabozantinib is recommended, within its marketing authorisation, as an option for treating progressive medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease, only if the company provides cabozantinib with the discount agreed in the patient access scheme.

From 26th June 2018, NHS England will routinely commission cabozantinib in line with these recommendations and according to a set of criteria which translates the NICE recommendation into a clinical guide as to use in practice. These treatment criteria can be found in section B of the national CDF list at https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/ or on the application form(s) on the Blueteq site.

It should be noted that cabozantinib received funding from the old CDF and has received interim funding from the new CDF from 15th February 2018 and will continue to receive funding until 26th June 2018 and so there may be a number of patients already commenced on treatment prior to the time it is routinely commissioned by NHS England.

In addition:

- Trusts must purchase cabozantinib at the agreed PAS discounted price.
- Trusts must complete a Blueteq form for all new patients receiving cabozantinib in order to confirm the patient meets the treatment criteria for use in NHS England. It should be noted that there is no requirement to re-register existing CDF patients in the routine commissioning section of the Blueteq system as these will be automatically transferred. However, there may be a delay in the information on these patients being visible as the transfer needs to occur out of working hours.
- Trusts must register cabozantinib use on SACT.
- Trusts must provide estimated patient numbers on cabozantinib who will transfer from the CDF to NHS England specialised commissioning hubs.
- Trusts must invoice cabozantinib only against its main specialised commissioning contract for all drug dispensed from 26th June 2018 and also ensure that the details are recorded against the main drug minimum data set (drug MDS) for that contract. Charging to the separate Cancer Drugs Fund drug MDS and accompanying invoices will cease for any dispensing from this date in this indication.

Any enquiries from NHS organisations about the patient access scheme should be directed to: medical.information.uk@ipsen.com.

I would be grateful if you could cascade this information to relevant clinical teams within your organisation to support the consistent adoption of the policy nationally.

Yours sincerely

Susan Bowler
Assistant Director, Specialised Commissioning
East Midlands NHS England – Midlands and East

Copies to: Provider Chief Executive
Provider Chief Pharmacist